Core Laboratories N.V. (CLB) 113.00 $CLB Oil Stocks to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Core Laboratories N.V. (CLB) 113.00 $CLB

Oil Stocks to Watch for Earnings on Jul 20: CLB, FTI, HAL
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 7:59AM CDT
A compilation of a list of three players - Core Laboratories NV, FMC Technologies and Halliburton Company - from the broader energy space that are expected to report quarterly numbers on Jul 20, 2016.
HAL: 42.76 (-0.18), FTI: 24.97 (unch), CLB: 113.00 (-0.49), SLB: 79.49 (-0.13)

Is Disappointment in Store for SAP SE (SAP) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 3:43PM CDT
SAP SE (SAP) is slated to report second-quarter 2016 results on Jul 20.
SAP: 85.71 (-0.44), QCOM: 61.04 (+0.03), INTC: 34.48 (+0.23), CLB: 113.00 (-0.49)

Should You Buy Core Laboratories (CLB) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 7:32AM CDT
Core Laboratories has earnings coming up pretty soon and events are shaping up quite nicely for its report.
CLB: 113.00 (-0.49)

Will Operating Expenses Hurt Ericsson's (ERIC) Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 8:49AM CDT
Telefonaktiebolaget LM Ericsson (publ) (ERIC) is set to report second-quarter 2016 results on Jul 19.
ERIC: 7.19 (-0.01), QCOM: 61.04 (+0.03), INTC: 34.48 (+0.23), CLB: 113.00 (-0.49)

Core Lab Announces Q3 2016 Quarterly Dividend
PR Newswire - Thu Jul 07, 3:15PM CDT
The Board of Supervisory Directors of Core Laboratories N.V. (NYSE: "CLB US" (Euronext Amsterdam Exchange: "CLB NA" has announced a cash dividend of $0.55 per share of common stock payable in the third quarter of 2016. This third quarter dividend would mean a total payout of $2.20 per share of common stock if maintained for the entire year. The quarterly $0.55 per share cash dividend will be payable on Monday, 15 August 2016, to shareholders of record on Monday, 18 July 2016. Dutch withholding tax will be deducted from the dividend at a rate of 15%.
CLB: 113.00 (-0.49)

Energy Spending May Resume: Stocks and ETFs in Focus
Sanghamitra Saha - Zacks Investment Research - Wed Jun 08, 11:58AM CDT
As oil prices recover, energy companies may start indulging in capital expenditure. Investors can play this likely pickup in spending with these stocks and ETFs.
TPYP: 22.35 (+0.05), NGL: 17.07 (-1.00), XES: 17.43 (+0.05), PXJ: 10.99 (+0.07), MLPJ: 8.09 (+0.19), PTEN: 19.22 (-0.15), CLB: 113.00 (-0.49), DO: 21.31 (+0.08), TEP: 47.21 (-0.76), TRP: 46.36 (+0.16), ENB: 41.01 (+0.45), CRZO: 33.45 (+1.10), PDCE: 55.74 (+0.91), AM: 25.07 (-0.35)

Are These Oil and Gas Attractive to Investors? - Seventy Seven Energy, Forum Energy Technologies, Core Laboratories, and Parker Drilling
PR Newswire - Thu May 26, 7:40AM CDT
The Oil and Gas Equipment and Services space, with its ups and downs, still surprises with opportunities. So today, ActiveWallSt.com has decided to shift focus back on the industry, and today's picks are: Seventy Seven Energy Inc. (NYSE: SSE), Forum Energy Technologies Inc. (NYSE: FET), Core Laboratories N.V. (NYSE: CLB), and Parker Drilling Co. (NYSE: PKD). To access our alert service, sign up for free today at:
PKD: 1.98 (-0.04), FET: 16.02 (+0.03), SSE: 0.16 (-0.01), CLB: 113.00 (-0.49)

Core Laboratories Set to Possibly Pullback After Yesterday's Rally of 1.10%
Comtex SmarTrend(R) - Mon May 23, 3:13PM CDT
Core Laboratories (NYSE:CLB) traded in a range yesterday that spanned from a low of $116.79 to a high of $119.32. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $118.70 on volume of 162,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLB: 113.00 (-0.49)

Core Laboratories Set to Possibly Rebound After Yesterday's Selloff of 3.32%
Comtex SmarTrend(R) - Thu May 12, 12:36PM CDT
Core Laboratories (NYSE:CLB) traded in a range yesterday that spanned from a low of $117.16 to a high of $121.27. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $120.03 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CLB: 113.00 (-0.49)

Core Laboratories (CLB) Upsizes Common Stock Offering
Zacks Equity Research - Zacks Investment Research - Thu May 12, 9:08AM CDT
Leading oilfield services company, Core Laboratories N.V. (CLB), declared the pricing of the public offering of 1,475,000 shares of its common stock.
BAK: 11.95 (+0.63), MDR: 4.83 (-0.09), SDPI: 1.42 (+0.05), CLB: 113.00 (-0.49)

Core Lab Announces Upsizing and Pricing of Public Offering of Common Stock
PR Newswire - Wed May 11, 6:59PM CDT
Core Laboratories N.V. (NYSE: "CLB US" (Euronext Amsterdam: "CLB NA" announced the upsized pricing of an underwritten public offering of 1,475,000 shares of its common stock. The underwriter intends to offer the shares from time to time for sale in one or more transactions on the New York Stock Exchange or the Euronext Amsterdam, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The total gross proceeds of the offering (before underwriter's discounts and commissions and estimated offering expenses) will be approximately $175 million. Core Lab granted the underwriter a 30-day option to purchase up to 221,250 additional shares of its common stock. The offering is expected to close on May 17, 2016, subject to customary closing conditions.
CLB: 113.00 (-0.49)

Core Lab Commences Offering Of Common Stock
PR Newswire - Wed May 11, 3:15PM CDT
Core Laboratories N.V. (NYSE: "CLB US" (Euronext Amsterdam: "CLB NA" today announced that it has commenced a registered underwritten public offering of 1,300,000 shares of its common stock. The underwriter intends to offer the shares from time to time for sale in one or more transactions on the New York Stock Exchange or on Euronext Amsterdam, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. Core Lab expects to grant the underwriter a 30-day option to purchase up to 195,000 additional shares of its common stock. The net proceeds from the offering will be used to repay a portion of the outstanding borrowings under our revolving credit facility.
CLB: 113.00 (-0.49)

SmarTrend Watching for Potential Rebound in Shares of Core Laboratories After 3.45% Loss
Comtex SmarTrend(R) - Wed May 04, 1:37PM CDT
Core Laboratories (NYSE:CLB) traded in a range yesterday that spanned from a low of $120.82 to a high of $128.73. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $127.10 on volume of 918,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CLB: 113.00 (-0.49)

Looking Back on Energy's Glory Days -- and Trying to Predict the Future
Tyler Crowe and Taylor Muckerman, The Motley Fool - Motley Fool - Tue May 03, 10:26AM CDT
It's throwback week for Industry Focus , and in this energy and materials episode, Sean O'Reilly, Taylor Muckerman, and Tyler Crowe look back on the gentler, more naive days of energy back in the summer of 2013. The trio explains why the price...
TSLA: 225.52 (-0.27), FSLR: 44.57 (-4.67), FCX: 12.34 (-0.05), CLB: 113.00 (-0.49)

Bare-Bones Customer Spending Cuts Deeply Into National Oilwell Varco, Inc.'s Results
Matthew DiLallo, The Motley Fool - Motley Fool - Thu Apr 28, 9:23AM CDT
Image source: National Oilwell Varco. Renewed pressure on oil prices last quarter resulted in very weak oil-field activities. Those weak market conditions had a very deep impact on National Oilwell Varco 's first-quarter results, which were...
NOV: 32.55 (-0.11), CLB: 113.00 (-0.49)

What Awaits Oil Drilling Stocks in Q1 Earnings: BHI, NOV
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 9:32AM CDT
We now wait to see how other energy sector bigwigs like Baker Hughes Inc. (BHI) and National Oilwell Varco, Inc. (NOV) perform when they report their Q1 results.
NOV: 32.55 (-0.11), CLB: 113.00 (-0.49), SLB: 79.49 (-0.13), BHI: 46.98 (-0.15)

Oil Prices: Is a "V-Shaped" Recovery on the Horizon?
Matthew DiLallo, The Motley Fool - Motley Fool - Sun Apr 24, 7:43AM CDT
Image source: Anadarko Petroleum. The price of crude oil has been battered for more than a year due to a vastly oversupplied oil market. However, that market is showing signs of improving and could be poised for a big second-half rebound. That's...
CLR: 44.98 (+0.10), CLB: 113.00 (-0.49), APC: 52.35 (-0.33)

Watch for Core Laboratories to Potentially Pullback After Gaining 4.77% Yesterday
Comtex SmarTrend(R) - Thu Apr 21, 1:50PM CDT
Core Laboratories (NYSE:CLB) traded in a range yesterday that spanned from a low of $119.39 to a high of $127.96. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $120.51 on volume of 829,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLB: 113.00 (-0.49)

Core Laboratories (CLB) Q1 Earnings in Line, Revenues Lag
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 10:06AM CDT
Oilfield services company Core Laboratories N.V.'s (CLB) first-quarter 2016 adjusted diluted earnings of 37 cents per share came in line with the Zacks Consensus Estimate.
PTR: 67.73 (-0.12), CLB: 113.00 (-0.49), VNR: 1.57 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading